This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Amid the global wave of digital transformation in the healthcare industry, China's market is evolving from a "primary sales hub" to a "primary innovation hub." Recently, Hong Chow, Executive Vice ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

The moves in China by the likes of Merck also come as the industry stares down a wave of generic drugs this year that has made the issue of securing new candidates all the more pressing.

the latest in a series of deals U.S. drugmakers have recently signed with China-based firms. Large drugmakers including Merck and Eli Lilly (LLY.N), opens new tab have turned to Chinese biotechs ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...

bought global rights to China-based United Laboratories International’s weight-loss drug candidate in a deal worth up to $2 billion. Merck last year signed a licensing deal worth up to $2 ...